Zhejiang Anglikang Pharmaceutical002940.SZValuation Analysis

As of Oct 19, 2026, Zhejiang Anglikang Pharmaceutical (002940.SZ) trades at a P/E of 38.20x, P/B of 2.64x, P/S of 3.48x, and a dividend yield of 1.12%.
Longitudinal percentile comparison: P/E sits at the 76th percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/B sits at the 40th percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/S sits at the 73rd percentile over the trailing 10Y window (vs. 52nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 52nd percentile within its industry and the 51st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.34%, ranking at the 36th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 36.0 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.12% comes from cash dividends, with an implied ~0.22% from buybacks — a fairly balanced mix of both channels. Zhejiang Anglikang Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.